PAA21 DEVELOPMENT OF A COST-UTILITY MODEL FOR COMPARING GINA STEP 3 ASTHMA MEDICATIONS BASED ON UTILITY AND SAFETY DATA DERIVED FROM A LARGE HEAD-TO-HEAD TRIAL OF MONTELUKAST AND SALMETEROL
Abstract
Authors
T Soroncz-Szabo SD Taylor L Nagy V Sazonov Kocevar